Regeneron forms consortium to fund exome sequencing

Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

UK govt invests in ‘world's largest’ genetics research project

12 September 2019 The world's ”largest genetics project” to tackle deadly diseases was launched yesterday, September 11, supported by funding from the UK government, charities and four pharmaceutical companies.

Americas

Alnylam and Regeneron unveil RNAi partnership

9 April 2019 Pharmaceutical companies Alnylam and Regeneron will collaborate on the development and commercialisation of RNA interference therapeutics.

Big Pharma

UK government announces life sciences deal; GSK and AstraZeneca invest

11 December 2017 The UK government has announced a deal between the life sciences sector and the government, aimed at ensuring that the “next wave of breakthrough treatments” and innovative medical research and technologies are created in the country.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Regeneron forms consortium to fund exome sequencing

More on this story

Editor's picks

Editor's picks

More features